{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T09:01:56Z","timestamp":1765530116953,"version":"3.48.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"DOI":"10.7759\/cureus.99024","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:58:41Z","timestamp":1765529921000},"source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin Perception Mapping Survey"],"prefix":"10.7759","author":[{"given":"Rajiv","family":"Kovil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Panikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehal","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlesh","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmen","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotika","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Kumar","family":"Kedia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravinda","family":"Jagadeesha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Chandratre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanhita","family":"Walawalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Kumar","family":"Virmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketan  K","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Muchhala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Gala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Sonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13915","article-title":"Heart failure among people with Type 2 diabetes mellitus: real-world data of 289\u00a0954 people from a diabetes database","volume":"37","author":"Stoyanova D","year":"2020","unstructured":"Stoyanova D, Stratmann B, Schwandt A, et al.. Heart failure among people with Type 2 diabetes mellitus: real-world data of 289\u00a0954 people from a diabetes database. Diabet Med. 2020, 37:1291-98. 10.1111\/dme.13915","journal-title":"Diabet Med"},{"key":"ref2","article-title":"IDF Diabetes Atlas 10th edition scientific committee","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas 10th edition scientific committee. IDF Diabetes Atlas [Internet] 10th edition. International Diabetes Federation, Brussels; 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1627_21","article-title":"Epidemiology of type 2 diabetes in India","volume":"69","author":"Pradeepa R","year":"2021","unstructured":"Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021, 69:2932-8. 10.4103\/ijo.IJO_1627_21","journal-title":"Indian J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA Heart Failure Guideline update","volume":"140","author":"Dunlay SM","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al.. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA Heart Failure Guideline update. Circulation. 2019, 140:e294-324. 10.1161\/CIR.0000000000000691","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06068-2","article-title":"Epidemiology of heart failure in diabetes: a disease in disguise","volume":"67","author":"Hoek AG","year":"2024","unstructured":"Hoek AG, Dal Canto E, Wenker E, Bindraban N, Handoko ML, Elders PJ, Beulens JW. Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia. 2024, 67:574-601. 10.1007\/s00125-023-06068-2","journal-title":"Diabetologia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10238-6","article-title":"Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence","volume":"28","author":"Palazzuoli A","year":"2023","unstructured":"Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2023, 28:585-96. 10.1007\/s10741-022-10238-6","journal-title":"Heart Fail Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039869","article-title":"Observational study investigating the prevalence of asymptomatic stage B heart failure in patients with type 2 diabetes who are not known to have coronary artery disease","volume":"11","author":"Oo MM","year":"2021","unstructured":"Oo MM, Tan Chung Zhen I, Ng KS, et al.. Observational study investigating the prevalence of asymptomatic stage B heart failure in patients with type 2 diabetes who are not known to have coronary artery disease. BMJ Open. 2021, 11:e039869. 10.1136\/bmjopen-2020-039869","journal-title":"BMJ Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjac028","article-title":"Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics","volume":"14","author":"Abudureyimu M","year":"2022","unstructured":"Abudureyimu M, Luo X, Wang X, et al.. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol. 2022, 14:10.1093\/jmcb\/mjac028","journal-title":"J Mol Cell Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.88a.20088","article-title":"The role of SGLT-2 inhibitors in managing type 2 diabetes","volume":"88","author":"Tsushima Y","year":"2021","unstructured":"Tsushima Y, Lansang MC, Makin V. The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleve Clin J Med. 2021, 88:47-58. 10.3949\/ccjm.88a.20088","journal-title":"Cleve Clin J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu B","year":"2022","unstructured":"Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022, 21:83. 10.1186\/s12933-022-01512-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia DS","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017, 24:73-79. 10.1097\/MED.0000000000000311","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"ADA Professional Practice Committee","year":"2025","unstructured":"ADA Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S239-51. 10.2337\/dc25-S011","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update","volume":"176","author":"Navaneethan SD","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, et al.. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023, 176:381-87. 10.7326\/M22-2904","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/20543581231217857","article-title":"Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the consolidated framework for implementation research","volume":"11","author":"Yi TW","year":"2023","unstructured":"Yi TW, O'Hara DV, Smyth B, Jardine MJ, Levin A, Morton RL. Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the consolidated framework for implementation research. Can J Kidney Health Dis. 2023, 11:20543581231217857. 10.1177\/20543581231217857","journal-title":"Can J Kidney Health Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG outcome trial","volume":"105","author":"Inzucchi SE","year":"2020","unstructured":"Inzucchi SE, Khunti K, Fitchett DH, et al.. Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG outcome trial. J Clin Endocrinol Metab. 2020, 105:3025-35. 10.1210\/clinem\/dgaa321","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"KDIGO CKD Work Group","year":"2024","unstructured":"KDIGO CKD Work Group. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102426","article-title":"Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study","volume":"68","author":"Forbes KA","year":"2024","unstructured":"Forbes KA, Hinton W, Feher M, et al.. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study. eClinicalMedicine. 2024, 68:102426.","journal-title":"eClinicalMedicine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20210281","article-title":"Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation","volume":"11","author":"Lau D","year":"2023","unstructured":"Lau D, Pannu N, Yeung RO, Scott-Douglas N, Klarenbach S. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation. CMAJ Open. 2023, 11:E101-109. 10.9778\/cmajo.20210281","journal-title":"CMAJ Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14255","article-title":"ACC\/AHA\/HFSA 2022 and ESC 2021 guidelines on heart failure comparison","volume":"10","author":"Behnoush AH","year":"2023","unstructured":"Behnoush AH, Khalaji A, Naderi N, Ashraf H, von Haehling S. ACC\/AHA\/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Fail. 2023, 10:1531-44. 10.1002\/ehf2.14255","journal-title":"ESC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430979-empagliflozin-perception-mapping-survey","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:58:41Z","timestamp":1765529921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430979-empagliflozin-perception-mapping-survey"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.99024","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}